We assessed the protective efficacy (PE) of three doses of B subunit-killed whole cell (BS-WC) and killed whole cell-only (WC) oral cholera vaccinesin a randomized, doubleblind trial among 62 285 children and women residing in rural Bangladesh. After one complete year of surveillance, 110 cases of cholera were detected in the placebo group, 52 in the we group (PE, 530/0; P < .0001), and 41 in the BS-We group (PE, 62%; P < .0001). Protection was greater for BS-We recipients than for we recipients only during the initial eight months of observation. Both vaccines conferred equivalent protection against cholera associated with life-threatening dehydration and against less severecholera. High-grade, sustained protection was observed in persons vaccinated when older than five years; in younger persons protection was transient. We conclude that BS-We and we vaccines confer significant protection against cholera, particularly in persons vaccinated when older than five years.
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Although parenteral vaccination against cholera is no longer regarded as a useful public health tool [1] , interest in developing new oral vaccines against cholera has persisted owing to recent data suggesting that local immunity in the intestine is most relevant for protection against cholera and that oral administration of antigens is the most efficient method of eliciting intestinal secretory antibodies [2] .
Oral cholera vaccines containing attenuated, live organisms are appealing as vaccine candidates be-cause these organisms have the ability to colonize the intestine and to elicit immune responses in a manner analogous to natural infections with Vibrio cholerae 01. However, vaccines containing live, attenuated organisms that have been developed thus far have been limited by side effects, particularly diarrhea [3] . Attention has therefore turned to development of killed oral vaccines, which can be administered without side effects.
Two oral cholera vaccines containing killed organisms have yielded promising results. These vaccines consist of killed V. cholerae 01 whole cells of both biotypes and serotypes, either with or without addition of the B subunit of cholera toxin [4] . Multiple doses of these agents elicited responses of intestinal secretory antibody to lipopolysaccharide and antibody to toxin comparable in magnitude to those seen in individuals with clinical cholera [5] . Moreover, neither agent has been found to cause any detectable side effects, despite experience in large numbers of volunteers from North America, Europe, and Bangladesh [5] [6] [7] [8] . Finally, North American volunteers given the vaccines and then challenged with virulent V. cholerae 01 showed significant protection against clinically severe diarrhea [6] .
Because of these background data the International Centre for Diarrhoeal Disease Research, Bangladesh, in collaboration with the government of Bangladesh and the World Health Organization, decided to conduct a large-scale field test of the two vaccines in a study area located in rural Bangladesh. Follow-up of participants during the initial four to six months after the third dose of vaccine or placebo demonstrated that the combined B subunit-killed whole cell vaccine (BS-WC) conferred 85010 protection against cholera and that the killed whole cell-only vaccine (WC) yielded 58070 protection [9] .
Over the remainder of the first year of surveillance, two major epidemics of cholera occurred, making an update of the assessment of vaccine efficacy desirable. Here we describe the findings of this analysis.
Materials and Methods
A detailed description of the design of the field trial and the compositions of the vaccines has been given elsewhere [9] . The trial was conducted in the Matlab field studies area of the International Centre for Diarrhoeal Disease Research, Bangladesh. Residents who were two to 15 years old and female subjects >15 y old (n = 124035) were randomly assigned to receive three doses of one of three agents.
Agents. Twooral vaccines were studied. The first vaccine (BS-WC)·consisted of 1 mg of cholera toxin B subunit together with 2.5 x 10 10 killed V. cholerae 01 whole cells from each of the following sources: heat-killed classical Inaba (strain Cairo 48), heatkilled classical Ogawa (strain Cairo 50), formalinkilled El Tor Inaba (strain Phil 6973), and formalinkilled classical Ogawa (strain Cairo 50) [4] . The second vaccine (WC) had identical whole cell constituents but lacked the B subunit. These two vaccines were compared with a placebo comprising a heatinactivated Escherichia coli K12 strain prepared in a concentration that matched the optical turbidity of the two cholera vaccines [9] .
Vaccination. Beginning in January 1985, vaCCI nation proceeded in three six-weekrounds, followed by a short one-week fourth round designed to give a third dose to two-dose recipients. Each agent was 61 stored at 4-8 C before delivery in the field and was administered with a solution of 2.8070 sodium bicarbonate and 1.1070 citric acid intended for buffering gastric acid [10] . The agents were labeled only as A, B, or C. During the conduct of the study, until the first analysis of the data in March 1986, the identities of the agents were unknown to all persons connected with the trial in Bangladesh. Thereafter the identities remained concealed from persons involved with field surveillance in Matlab.
Altogether, 89 596 persons took at least one dose of a study agent. Among the 34 439 remaining ageand gender-eligible persons, 31 238 persons were absent or refused to participate, and 3201 persons were excluded because they were pregnant or were too ill to leave their beds on the day of vaccination. During vaccination, physicians were stationed throughout the trial area to treat possible side effects and to refer such cases to a treatment center where systematic surveillance for such events was maintained.
Surveillance. Surveillance for diarrhea was conducted at all three diarrheal treatment centers serving the Matlab population. At each center, clinical data and fecal specimens were obtained from all individuals with diarrhea who resided in the vaccine field trial area. The specimens were processed with conventional microbiological techniques for identifying V. cholerae 01 and for determining the biotype and serotype of each isolate [11] . Whenever V. cholerae 01 was isolated, a special team was dispatched to the stated home of the patient to determine whether the person whose identity had been given in the treatment center had indeed sought care on the date of presentation for care.
Analyticstrategies. The primary purpose of the present analysis was the evaluation of vaccine efficacy during the first year of follow-up after receipt of three complete doses of an assigned agent. To be counted as having a case of cholera in this analysis, a subject must have (1) presented for treatment of diarrhea whose onset was 14-365 d after the third dose; (2) described at least three loose stools in the 24-h period before presentation or, if one or two loose stools or an indeterminate number of loose stools were described, must have manifested at least two objective signs of dehydration on initial physical examination (feeble or absent pulse, tenting of skin, sunken eyes, or dry mucous membranes); (3) described the diarrhea as nonbloody; (4) produced a fecal specimen yielding V.cholerae 01; and (5) had his or her identity confirmed at the time of the field- check. If the date of onset of diarrhea for one visit for treatment was seven or fewer days from the date of discharge for the previous visit for treatment, the second visit was grouped with the previous visit as part of the same diarrheal episode. Evaluations of vaccine efficacy thus pertain to treated episodes of cholera rather than to visits for treatment of cholera per se.
Protection against cholera associated with potentially life-threatening dehydration was an outcome of particular interest. Accordingly, before analyzing the data, we defined dehydration as "significant" (e.g., life-threatening) if, at the time of a visit for treatment, an absent or feeble pulse was noted and at least one additional objective sign of dehydration was described (poor skin turgor, sunken eyes, or dry mucous membranes). Patients not meeting these criteria wereclassified as having "nonsignificant" dehydration.
Vaccine efficacy was expressed as the percent protective efficacy (PE): PE = (l -[incidence of cholera in vaccinees/incidence of cholera in controls]) X 100. When the PE of three doses of vaccine for any particular interval of follow-up was evaluated, denominators for calculating the incidence of cholera were the populations still at risk at the beginning of the interval under analysis, after persons who had emigrated, died, or acquired cholera before the interval were excluded. The ratio in the expression for PE was thus the relative risk of cholera in vaccinees vs. controls.
In secondary analyses, assessment of efficacy of one and two doses of vaccines was of interest. In these analyses a high fraction of persons had to be right-censored at the time of taking the next offered dose. Accordingly, expression of denominators for the incidence of cholera in person-time units was necessary. For calculating person-days of follow-up after receipt of a particular dose, follow-up was rightcensored at the earliest of emigration, death, onset of cholera, the next dose, or the end of the followup interval under analysis. The ratio for PE thereby became an incidence density ratio for cholera in vaccinees vs. controls, which, because of the rarity of cholera, closely approximated a relative risk [12] .
The statistical significance of differences of proportions was assessed with the '1} test or, where appropriate, Fisher's exact test. For comparisons of incidence density values, large-sample Z-tests were used [12] . Confidence intervals for PE were calculated with test-based methods [12, 13] . The sign test Clemens et al. was used for evaluating paired comparisons of vaccine efficacy against classical Ogawa vs. EI Tor Ogawa V. cholerae 01 [14] .
To assess the distinctiveness of PE values for different subgroups, we used unconditional logistic regression, taking the occurrence of cholera as the dependent variable and vaccination status as well as covariates defining the subgroups as independent variables. In this model the exponential of the coefficient for the vaccination term approximated the relative risk of cholera in the vaccinated vs. the placebo groups. The statistical significance of differences of relative risks, and thereby of values for PE, in different subgroups was then evaluated by the likelihood ratio test, comparing models with and without interaction terms containing the vaccination variable and the covariates defining relevant subgroups [12] .
Two primary hypotheses were evaluated: (1) that the incidence of cholera is lower among persons receiving three complete doses of BS-WC than among persons receiving three complete doses of placebo and (2) that the incidence is lower among recipientsof three complete doses of WC than among recipients of three complete doses of placebo. In accordance with Bonferroni's corrections for multiple comparisons, rejection of the null hypothesis of no efficacy for these two primary comparisons required P < .025 (one-tailed) [15] . A value of P < .05 (onetailed) was the threshold for statistical significance for comparisons of cholera attack rates between the two vaccinated groups, as well as for vaccine efficacy calculations in subgroup analyses. One-tailed tests were used for these comparisons because the only questions of concern were whether each vaccinated group experienced a lower cholera attack rate than that for the placebo group and whether the B subunit component increased the efficacy conferred by WC alone. For comparisons not involving these a priori hypotheses, statistical tests were interpreted in a two-tailed fashion. Ninety-five percent confidence intervals were calculated in a one-tailed or a two-tailed fashion according to the same rules [16] . Because one-tailed confidence limits all extend from the lower boundary of the interval to 100070 efficacy, only lower boundaries are cited in the results for the one-tailed intervals [16] .
Results
Pattern of cholera during the evaluation period. Figure 1 displays the monthly frequencies, Comparability of the treatment groups and absence of side effects. The original randomization of the 124 035 age-and gender-eligible residents of Matlab created three groups that were comparable in size and that were qualitatively similar in the distribution of several risk factors for cholera. The 62 285 participants took three complete doses of their assigned agents. These participants formed three groups (table 1)that were also nearly identical in size and with respect to the distribution of age, gender, and several additional baseline variables known to be risk factors for cholera [17] . During the 12 mo of follow-up, 2.7070 of each group emigrated from the study area, and the groups remained similar with respect to these risk factors. As reported elsewhere [9] , analysis of different complaints detected by surveillance for side effects during vaccination revealed similar frequencies for the three groups, a finding confirming results from the pretest indicating that no side effect could be attributed to either vaccine [8] .
Vaccine efficacy during the first year after the third dose. Table 2 gives the occurrence of cholera during the period 14-365 d after receipt of the third dose among participants ingesting three complete doses of their assigned agents. During this interval, 110 episodes occurred in the placebo group, 41 episodes occurred in the BS-WC group (PE, 62070; P < .0001 among all residents of the vaccine trial area, of episodes of diarrhea that were associated with excretion of V. cholerae 01 and that were detected in the three treatment centers. Data are presented for the interval between April 1985 and May 1986. During this interval 4349 episodes of diarrhea were treated among residents of the area. V. cholerae 01 was isolated in 1294(30070) of the episodes. The pattern observed between April and September 1985 reflected the tail end of the annual spring epidemic in April, followed by a steady occurrence of cholera episodes thereafter. Subsequently, two major epidemics were observed: a winter epidemic between October 1985 and February 1986 and a spring epidemic that began in April 1986 and extended through May 1986.
Classical Ogawa and EI Tor Ogawa organisms were isolated in 1192 (92070) of the cholera episodes. Diarrhea associated with EI Tor Ogawa organisms displayed a steady occurrence during most of the period of observation, whereas the incidence of diarrhea associated with classical Ogawa organisms peaked Persistence of efficacy with time. Table 3 presents data for PE in relation to serial time after the third dose, with the year after the third dose divided into three equal periods. It appeared that PE declined for BS-We, from 79% in the first period to rv60% thereafter. For we, in contrast, PE showed no clear trend, beginning at 52% in the first period, dipping to 34% in the second period, and rising to 61% in the final period. However, for neither vaccine did these differing values for efficacy by period reach statistical significance. Although the overall incidence of cholera in the Bs-we and we groups at one year of follow-up was not significantly different, the incidence was lower in the BS-We group than in the we vaccine group during the initial eight months of serial follow-up (P < .05 [one-tailed)), with no significant difference thereafter. Because the risk of cholera varied widely by season, evaluation of protection conferred by each vaccine in calendar time during each of three distinctive epidemiological periods (figure 1)-a "preepidemic" period (April-September 1985) during which cholera was detected at a steady rate; and "winter" (October 1985-February 1986) and "spring" (March-May 1986)epidemics, when impressive rises in cholera rates were noted -was also of interest. For the BS-We group, analysis of the data by season revealed an initial level of 85%, which declined to 52070 during the winter epidemic and to 63% in the spring epidemic (P< .05 [two-tailed] for comparison of PE NOTE. Serial time is the no. of days after receipt of the third dose. Preepidemic was defined as April-September 1985, the winter epidemic was defined as October 1985-February 1986, and the spring epidemic was defined as March-May 1986. Data are no. of cholera episodes detected during the interval/no. of persons at risk at the beginning of the interval; numbers in parentheses are PE values. * P < .001 (one-tailed) for PE value given. t P < .05 (one-tailed) for PE value given.
+P < .01 (one-tailed) for PE value given. § P < .0001 (one-tailed) for PE value given.
for the preepidemic season vs. the remainder of the follow-up period). The pattern for we efficacy by season was similar to that observed in serial time and did not reveal statistically distinctive values for the three seasons. The cholera attack rate in the BS-We group appeared to remain lower than that for the we group throughout the preepidemic and winter epidemic periods (P = .05 [one-tailed)), but the rates were similar during the spring epidemic.
Efficacy against different types of cholera. * P < .05 (one-tailed) for PE value given. t p < .001 (one-tailed) for PE value given. t p < .01 (one-tailed) for PE value given.
§ P < .0001 (one-tailed) for PE value given.
I I Includes one subject from whom both classical Ogawa and EI Tor Ogawa were isolated. curring in 74 [67010] placebo episodes) and because El Tor isolates were uncommon during the winter epidemic, when the differences in vaccine efficacy by biotype were largest.
Relation ofefficacy to severity ofcholera and to age at vaccination. Each vaccine appeared to protect equally well against cholera causing significant (e.g., potentially life-threatening) dehydration and against cholera causing lesser degrees of dehydration ( tailed)). The low overall efficacy observed when each vaccine was administered to the 36-71-mo age group reflected an initial protective effect in the preepidemic period (PE for BS-WC, 100%; PE for WC, 45%), with loss of protection during the epidemic periods. In contrast, no decline in efficacy with time was observed in the younger (24-35 mo) and older (>71 mo) age groups.
Vaccine efficacy among persons receiving one or two doses. Although participants were not randomized to receive various numbers of doses, exploration of whether fewer than three doses seemed to confer significant protection was nevertheless of in- NOTE. Epidemic refers to the combined winter and spring epidemic periods (October 1985-May 1986). Data are no. of cholera episodes detected/no. of subjects at risk at the beginning of the interval; numbers in parentheses are PE values. Age groups are those at the beginning of the vaccination program. * p < .01 (one-tailed) for PE value given. t p < .05 (one-tailed) for PE value given. t p < .05 (two-tailed) for difference in PE between children 24-35 mo old and those 36-71 mo old. § P < .0001 (one-tailed) for PE value given.
terest. We assessed the occurrence of cholera during the year after ingestion of one or two complete doses of an assigned agent. The three groups were similar in number and in the distribution of risk factors when compared at the time of the first and second doses. Episodes of cholera were analyzed only if the onset of diarrhea was at least 14 d after the cited dose and if no subsequent dose had intervened between the date of onset and the date of the cited dose. Little protection was observed after one dose of either vaccine or after two doses of we (PE for each vaccine-placebo comparison, 16070-17070). In contrast, five episodes were noted in two-dose recipients of BS-We, as opposed to 19episodes after two doses of placebo, for a PE of 74% (P < .01 [one-tailed]).
Twelve of the 19 cases observed in the two-dose placebo group occurred in the second six months of follow-up, during which the efficacy of two doses of BS-We remained substantial (PE, 67%).
Discussion
Our results demonstrate that oral ingestion of three doses of killed antigens of V. cholerae 01 induces significant protection against cholera sufficiently severe to prompt solicitation of clinical care. Vaccine efficacy, which was clearly evident one year after the third dose, was nearly identical against infections associated with potentially life-threatening dehydration and against infections associated with less severe symptoms.
Implications of the epidemiological pattern of cholera during the trial. As judged from the placebo group, the overall attack rate for the year of follow-up (5.3 cholera episodes per 1000 placebo recipients) was more than three times the usual rate for persons in the same age-gender groups in Matlab [17] , and an increase in incidence occurred in both children and adults. Part of the observed increase in the incidence of cholera, in comparison with earlier periods of surveillance in Matlab, may have resulted from easier accessibility to care for diarrhea, due to the addition of two diarrheal treatment centers in Matlab after the earlier studies [17] .
However, we believe that the elevated incidence of cholera observed during the trial reflected a genuine increase in occurrence of cholera in the community, because about three-quarters of the cholera episodes noted in all three treatment centers during the trial were detected in Matlab Hospital, the only treatment center used for the earlier cholera surveillance studies. Moreover, 1'\J60% of patients with cholera treated in the two newer centers during the trial presented with moderate-to-severe dehydration and would undoubtedly have sought care at Matlab Hospital had the two newer centers not been in existence. This unusually high incidence of cholera and the fact that the overall results for vaccineefficacy at one year primarily reflected the heavy case load observed in the last half of the year of follow-up indicate that the trial took place under epidemiological conditions that probably made overall estimates of "one-year efficacy" conservative.
Possibleprotective effect ofB subunit. For persons ingesting three doses, B subunit appeared to enhance the protection conferred by killed whole cells, but this enhancement was substantial only during the initial few months after vaccination and was no longer evident in the final four months of followup. In contrast, for persons taking only two doses, the addition of B subunit appeared to augment the efficacy of whole cells alone during the entire year of follow-up. Neither vaccineappeared to confer substantial protection after a single dose.
Although comparing patterns of efficacy after differing numbers of doses is made difficult by the small number of cases in the one-dose and two-dose analyses and by the fact that the trial did not randomize groups to receive one, two, or three doses, analyses of both two and three doses suggest that B subunit-induced immunity augmented the protective effect of antibacterial immunity elicited by whole cells. In addition, the sustained augmentation of efficacyby B subunit in the two-dose comparison raises the possibility that B subunit may act as an adjuvant in enhancing immune responses to whole cells. Interestingly, volunteers given BS-We showed substantially greater mucosal secretory IgA antibody responses to vibrio lipopolysaccharide than did volunteers given only we, and cholera toxin has been demonstrated to be a potent adjuvant in augmenting mucosal secretory antibody responses to various oral antigens [6, 18] . Relation of vaccine efficacy to age. The gradient of vaccine efficacy seen for younger children compared with older children and adults is consistent with past evaluations of parenteral cholera vaccines, particularly those given in a single dose [19] [20] [21] . This gradient has been attributed to the greater immunologic "naivete" of young children, who are thought to have had a limited number of past natural exposures to cholera and who are thus presumed to exhibit true primary responses to vaccination [22] . In contrast, older children and adults living in an area endemic for cholera are likely to have been exposed previously to cholera, and vaccine efficacy may reflect secondary or booster effects of the vaccine in these age groups.
However, more detailed age-specific evaluations of vaccine efficacy in young children revealed a considerably more complex pattern (table 6). For both vaccines, children 24-35 mo old at vaccination had levels of protection at one year of follow-up that were similar to levels seen in adults. In contrast, children vaccinated between the ages of 36 and 71 mo had substantial protection in the preepidemic period; this protection disappeared during the ensuing epidemic periods. Although the rapid decline of efficacy observed for children 36-71 mo old resembles a pattern observed for young children given parenteral cholera vaccine and may reflect the inability of the vaccines to induce significant immunologic memory in children in this age group [19] , the high efficacy seen in the 24-35-mo age group was unexpected.
That the higher observed efficacy for children vaccinated in the 24-35-mo age group occurred by 67 chance is unlikely because levels of efficacy were elevated for both vaccines in this age group and because the higher efficacy for BS-We given to twoyear-olds was statistically distinct from the lowerlevel of efficacy observed when it was administered at 36-71 mo of age. Moreover, that postvaccination exposure to cholera was lower in the children vaccinated between 24 and 35 mo of age is unlikely because they exhibited an annual incidence rate of cholera (16.3 cases per 1000 placebo recipients) far greater than that for any other age group.
At least two possible explanations can be offered. First, breast-feeding might have contributed to the higher protection of two-year-olds because breast milk of rural Bangladeshi mothers is known to contain antibodies to V. cholerae 01 and might thereby augment the protection provided by the vaccines [23] . Just before the onset of symptoms of cholera, none of the eight cases detected in children given BS-We or we at two years of age were in breast-fed children, whereas three of the 14 children of comparable age given placebo were breast-fed. Although based on a small number of subjects, these data suggest that vaccinated children who are breast-fed at the time of exposure to cholera are nearly completely protected against becoming ill. However, if we assume equal proportions of breast-fed children among children who took vaccine and among those who took placebo at 24-35 mo of age, it is clear that breast-feeding does not totally explain the high efficacy in this age group, because children who had been given BS-We but were not breast-fed just before symptomatic cholera still manifested 82070 protection (11 cases in the placebo group vs. two cases in the BS-We group), whereas those ingesting we exhibited 45% protection (11 cases vs. six cases). Another possible explanation for the high vaccine efficacy seen in children vaccinated at 24-35 mo of age might be the high occurrence of infections due to heat-labile, toxin-producing enterotoxigenic E. coli in young children, an occurrence that might elicit antibody responses to toxin that cross-protect against cholera toxin and that might thereby augment vaccine-induced protection [24, 25] .
Effect of biotype on vaccine efficacy. For diarrheal episodes associated with Ogawa organisms, each vaccine exhibited a somewhat higher level of protection against classical organisms than against El Tor organisms. This observation could be related to the fact that each vaccine contained three-fourths killed classical vibrios and one-fourth killed El Tor vibrios. However, the differential protection against infections due to the two biotypes of V. cho/erae 01 was unexpected, because past evaluations of parenteral vaccines had suggested that vaccines composed of classicalorganisms cross-protect against infections due to £1Tor organisms [26] and because experimental cholera in animals has produced solid protection against subsequent challenge with V. cho/erae 01 of the heterologous biotype [27] .
Relation toprevious studies. Our results indicate that three doses of oral cholera BS-WC and WC induced protection that was clearly evident one year after the third dose and that was apparently more durable than protection conferred by a parenteral vaccine of average potency, similar to commercially available vaccine, when it was tested in the same field area [19] . On the other hand, certain plain [28] and adjuvanted [29, 30] parenteral whole cell cholera vaccines have exhibited moderate efficacy at one year of follow-up in past vaccine trials. However, these vaccines failed to find a role in public health practice, either because of significant reactogenicity [28] or because of limited long-term efficacy [29, 30] .
Comparison of the performance of oral and parenteral vaccines tested in different field trials, however, is at best a highly speculative exercise, and a direct comparison of the vaccines in the same trial would be necessary for drawing firm conclusions.
Needfor furtherstudies. Further evaluation will be needed to determine whether one or both oral vaccines will have a role in public health programs. Although the persistence of protection at one year is encouraging, several years of follow-up will be necessary to assess long-term efficacy. The apparently equivalent protection conferred by two and three doses of BS-WC, which has important implications for the practical usefulness of this vaccine, requires confirmation in future studies specifically designed to evaluate this possibility. Work is also required to modify the current liquid formulation of the vaccines in a fashion that permits convenient storage, distribution, and administration. Finally, consideration will have to be given to testing booster doses of vaccine or finding some other method of augmenting immunity in young children, in whom protection rapidly waned with time after vaccination.
